Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 2 countries.
Hsuan-Yu J LinSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0003-2992-7793
Rachana Rao BattajeDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Jinlong TanSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Munikumar DoddareddySydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Hemendra Pal Singh DhakedDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Shalini SrivastavaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Bryson A HawkinsSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-0280-039X
Laith Mohammad Hilal Al-ShdifatSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-3953-0039
David E HibbsSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Dulal PandaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Paul W GroundwaterSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-4932-2030
The University of Sydney · AUIndian Institute of Technology Bombay · IN
Funding
Department of Science and Technology CRG/2019/000566
6 · The paper itself
Abstract
Multi-drug resistance is increasing in the pathogenic bacterium
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of 2',6-Bis(4-hydroxybenzyl)-2-acetylcyclohexanone, a Novel FtsZ Inhibitor. · full record | OpenQuestion